14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
XMAR vs XNOV: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, FT Vest U.S. Equity Enhance & Moderate Buffer ETF - November (XNOV) is the stronger overall head-to-head candidate over FT Vest U.S. Equity Enhance & Moderate Buffer ETF - March (XMAR) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). XMAR carries a Unified Composite Score of 55.0/100 (HOLD) at $43.57 (N/M Forward P/E, N/A operating margin), whereas XNOV carries 51.4/100 (HOLD) at $40.80 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While XMAR currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. XNOV 51.4/100 HOLD), XNOV captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
Technical & Structure Timing Caution: XMAR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 45.5); meanwhile XNOV trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 60.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XMAR vs XNOV. Trailing 12-month operating profitability (XMAR N/A vs XNOV N/A) and valuation multiples (XMAR N/M vs XNOV N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ XMAR vs XNOV Key Questions & Quantitative Answers
As of Nov 16, 2026, FT Vest U.S. Equity Enhance & Moderate Buffer ETF - November (XNOV) is the stronger overall head-to-head candidate over FT Vest U.S. Equity Enhance & Moderate Buffer ETF - March (XMAR) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). XMAR carries a Unified Composite Score of 55.0/100 (HOLD) at $43.57 (N/M Forward P/E, N/A operating margin), whereas XNOV carries 51.4/100 (HOLD) at $40.80 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While XMAR currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. XNOV 51.4/100 HOLD), XNOV captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: XMAR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 45.5); meanwhile XNOV trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 60.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
XMAR and XNOV split Growth & Scale metrics: XMAR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with XNOV at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, XMAR generates N/A in USD-normalized revenue versus N/A for XNOV. In operating R&D and SG&A reinvestment, XMAR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XNOV.
XMAR and XNOV trade at balanced relative valuation multiples. XMAR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas XNOV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XMAR (N/A ROE) versus XNOV (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, XMAR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 6% Vol realized risk). By comparison, XNOV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 3% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.